The safety of tiotropium in the form of moist mlžiny (Respimat inhaler) studies demonstrated TIOSPIR
2013
Abstract
Tiotropium since its introduction in the treatment of COPD in 2002, became an important drug, considered by many to be the first drug of choice. Many studies have been shown to have a good effect on the improvement in pulmonary function, reduce the number of exacerbations and improve quality of life.